Читать книгу 40 Years of Continuous Renal Replacement Therapy - Группа авторов - Страница 12

Continuous arteriovenous hemofiltration (CAVH) was first proposed in 1977 and immediately became an important alternative treatment for AKI in patients in whom peritoneal dialysis or hemodialysis was clinically or technically precluded [3]. This opened the doors of intensive care units to extracorporeal treatments, which experienced a flourishing evolution in subsequent years. In the mid-1980s, the technology of CAVH was extended to infants and children, and newly designed hemofilters permitted the application of the technique even to newborns [4]. CAVH presented important advantages over intermittent hemodialysis, such as hemodynamic stability with slow continuous volume and solute control. Specific filters with reduced flow resistance that were adequate to operate in an arteriovenous modality were designed to improve performance. In spite of technological ameliorations in the filter and membrane design, CAVH presented limited ultrafiltration and solute clearance as well as risk derived from arterial cannulation.